Image
Recommendation
Management of the axilla – Indications for further axillary treatment #2
Discuss the benefits and risks of having no further axillary treatment after mastectomy or after breast-conserving surgery in patients who have one or two sentinel lymph node macrometastases and have been advised to have radiation therapy and adjuvant systemic therapy.
Discuss the benefits and risks of having no further axillary treatment after primary breast-conserving surgery (within clinical trials where available) with women who: have 1 or 2 sentinel lymph node macrometastases and have been advised to have whole breast radiotherapy with systemic therapy (which may be endocrine therapy)
How this guidance was developed
This recommendation was adopted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording ('Discuss') indicative of the need for shared decision-making by the source guideline authors. The information on clinical trials was removed as this aspect of care is covered in a separate recommendation, and in the key principles.
Management of the axilla – Indications for further axillary treatment #2
Recommendation
Discuss the benefits and risks of having no further axillary treatment after mastectomy or after breast-conserving surgery in patients who have one or two sentinel lymph node macrometastases and have been advised to have radiation therapy and adjuvant systemic therapy.
Principles in action
Patient-centred care
Image
Communication
This recommendation was adopted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording ('Discuss') indicative of the need for shared decision-making by the source guideline authors. The information on clinical trials was removed as this aspect of care is covered in a separate recommendation, and in the key principles.